ENTX · Entera Bio Ltd.
$3.23
-0.70 (-17.73%)
At close · Jul 28
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's current capital resources do not include the capital required to fully fund the Company's proposed Phase 3 program for EB613 in osteoporosis. These factors raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$160.47M
Shares
49.23M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Miranda Toledano | CEO | $1,149 |
| Dana Yaacov-Garbeli | Chief Financial Officer | $438 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Miranda Toledano | CEO | $950 |
| Hillel Galitzer | COO | $459 |
| Dana Yaacov-Garbeli | Chief Financial Officer | $311 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Phillip Schwartz | Former President of R&D | $782 |
| Miranda Toledano | CEO | $679 |
| Hillel Galitzer | COO | $621 |
| Dr. Hillel Galitzer | COO | $621 |
| Dana Yaacov-Garbeli | Chief Financial Officer | $381 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Spiros Jamas | CEO | $1,143 |
| Dr. Phillip Schwartz | Former President of R&D | $685 |
| Dr. Hillel Galitzer | COO | $640 |
| Miranda Toledano | CEO | $82 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Phillip Schwartz | Former President of R&D | $610 |
| Dr. Hillel Galitzer | COO | $527 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Geno H. Germano | Class III director | Appointed | 2026-07-16 |
| Steven D. Rubin | Class III director | Appointed | 2026-07-16 |
| Sean Ellis | Class III director | Appointed | 2026-07-16 |